MA41449A - Polythérapies pour le traitement de cancers - Google Patents

Polythérapies pour le traitement de cancers

Info

Publication number
MA41449A
MA41449A MA041449A MA41449A MA41449A MA 41449 A MA41449 A MA 41449A MA 041449 A MA041449 A MA 041449A MA 41449 A MA41449 A MA 41449A MA 41449 A MA41449 A MA 41449A
Authority
MA
Morocco
Prior art keywords
polytherapies
cancers
treatment
Prior art date
Application number
MA041449A
Other languages
English (en)
Inventor
Paolo Julie A Di
Randall Mark Jones
Daniel B Tumas
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55398445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA41449A publication Critical patent/MA41449A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA041449A 2015-02-03 2016-01-28 Polythérapies pour le traitement de cancers MA41449A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562111604P 2015-02-03 2015-02-03

Publications (1)

Publication Number Publication Date
MA41449A true MA41449A (fr) 2017-12-12

Family

ID=55398445

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041449A MA41449A (fr) 2015-02-03 2016-01-28 Polythérapies pour le traitement de cancers

Country Status (25)

Country Link
US (2) US20160220573A1 (fr)
EP (1) EP3253385A1 (fr)
JP (1) JP2018503653A (fr)
KR (1) KR20170104616A (fr)
CN (1) CN107205992A (fr)
AU (1) AU2016215643A1 (fr)
BR (1) BR112017016019A2 (fr)
CA (1) CA2974828A1 (fr)
CL (1) CL2017001943A1 (fr)
CO (1) CO2017007662A2 (fr)
CR (1) CR20170352A (fr)
CU (1) CU20170099A7 (fr)
EA (1) EA201791516A1 (fr)
EC (1) ECSP17048849A (fr)
GT (1) GT201700167A (fr)
IL (1) IL253573A0 (fr)
MA (1) MA41449A (fr)
MD (1) MD20170073A2 (fr)
MX (1) MX2017009724A (fr)
PE (1) PE20171241A1 (fr)
PH (1) PH12017550063A1 (fr)
SG (1) SG11201706107SA (fr)
SV (1) SV2017005489A (fr)
TW (1) TW201639573A (fr)
WO (1) WO2016126552A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068258A1 (fr) 2008-12-08 2010-06-17 Cgi Pharmaceuticals, Inc. Inhibiteurs d'imidazopyrazine syk
MX350010B (es) 2010-03-11 2017-08-23 Gilead Connecticut Inc Inhibidores syk de imidazopiridinas.
NZ715776A (en) * 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
CA2919479C (fr) 2013-07-31 2017-08-22 Gilead Sciences, Inc. Inhibiteurs syk
EP3076976B1 (fr) 2013-12-04 2020-09-02 Gilead Sciences, Inc. Méthode de traitement du cancer
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
MX2017000610A (es) 2014-07-14 2017-04-27 Gilead Sciences Inc Metodos combinados para tratar canceres.
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018053190A1 (fr) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Inhibiteurs de syk
US10759798B2 (en) * 2016-09-14 2020-09-01 Hangzhou Solipharma Co., Ltd. ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof
WO2018200841A1 (fr) * 2017-04-28 2018-11-01 Actinium Pharmaceuticals, Inc. Méthode de traitement du cancer à l'aide d'un inhibiteur de bcl-2 en association avec une radioimmunothérapie à émission alpha
US11384082B2 (en) 2017-08-25 2022-07-12 Kronos Bio, Inc. Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors
WO2019139902A1 (fr) 2018-01-10 2019-07-18 Zeno Royalties & Milestones, LLC Composés benzamide
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
KR20220034782A (ko) 2019-06-12 2022-03-18 주노 쎄러퓨티크스 인코퍼레이티드 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
CN112891353B (zh) * 2019-12-04 2024-01-30 苏州亚盛药业有限公司 药物组合及其用途
WO2022133030A1 (fr) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Polythérapie de thérapie cellulaire et d'inhibiteur de bcl2
EP4316494A4 (fr) * 2021-04-05 2025-04-09 Pinotbio, Inc. Polythérapie à basede 4'-thio-5-aza-2'-désoxycytidine et de vénétoclax
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
GB0326780D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
HRP20161751T1 (hr) 2004-05-13 2017-04-07 Icos Corporation Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
CA2606147C (fr) 2005-05-12 2011-07-05 Abbott Laboratories Promoteurs d'apoptose
EP2185198B1 (fr) 2007-08-02 2015-01-14 Gilead Biologics, Inc. Inhibiteurs/anticorps dirigés contre lox et loxl2, et procédés d'utilisation associés
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
US8450321B2 (en) * 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
LT2716157T (lt) * 2008-12-08 2016-09-12 Gilead Connecticut, Inc. Imidazopirazino syk inhibitoriai
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2477972A1 (fr) 2009-09-20 2012-07-25 Abbott Laboratories Formes cristallines et solvates d'abt-263 pour une utilisation dans le traitement de maladies se rapportant à une protéine bcl-2
RU2015108348A (ru) 2010-02-04 2015-07-20 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
WO2011133668A2 (fr) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Méthodes et compositions utilisées pour le traitement du cancer
NZ701444A (en) 2010-08-27 2016-06-24 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
WO2012071336A1 (fr) 2010-11-23 2012-05-31 Abbott Laboratories Sels et formes cristallines d'un agent inducteur d'apoptose
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
JP2014528451A (ja) 2011-10-04 2014-10-27 ギリアード カリストガ エルエルシー Ｐｉ３ｋの新規キノキサリン阻害剤
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (fr) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions et procédés de traitement d'une maladie avec (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phényl-3,4-dihydroquinazoline-2-yl)éthyl)amino)pyrimidine-5-carbonitrile
AU2013302617A1 (en) * 2012-08-14 2015-02-05 Gilead Calistoga Llc Combination therapies for treating cancer
HK1212240A1 (en) * 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
TW201427995A (zh) 2012-09-24 2014-07-16 Gilead Sciences Inc 抗ｄｄｒ１抗體
CA2895782C (fr) 2012-12-21 2017-08-22 Gilead Calistoga Llc Pyrimidine aminoalkyl-quinazolones substituees en tant qu'inhibiteurs de phosphatidylinositol 3-kinase
EP2935246B1 (fr) 2012-12-21 2018-07-25 Gilead Calistoga LLC Inhibiteurs d'isoquinolinone phosphatidylinositol 3-kinase ou de quinazolinone phosphatidylinositol 3-kinase
PL3008053T3 (pl) 2013-06-14 2018-08-31 Gilead Calistoga Llc Inhibitory 3-kinazy fosfatydyloinozytolu
NZ715776A (en) 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
JP6153667B2 (ja) 2013-07-30 2017-06-28 ギリアード コネチカット， インコーポレイテッド Ｓｋｙ阻害剤の製剤

Also Published As

Publication number Publication date
KR20170104616A (ko) 2017-09-15
BR112017016019A2 (pt) 2018-03-20
US20160220573A1 (en) 2016-08-04
IL253573A0 (en) 2017-09-28
MD20170073A2 (ro) 2018-02-28
CO2017007662A2 (es) 2017-10-20
ECSP17048849A (es) 2017-10-31
PE20171241A1 (es) 2017-08-24
CR20170352A (es) 2017-09-29
MX2017009724A (es) 2017-11-17
CN107205992A (zh) 2017-09-26
CU20170099A7 (es) 2018-03-13
GT201700167A (es) 2017-11-02
WO2016126552A1 (fr) 2016-08-11
US20180117052A1 (en) 2018-05-03
AU2016215643A1 (en) 2017-08-10
PH12017550063A1 (en) 2018-02-05
JP2018503653A (ja) 2018-02-08
EP3253385A1 (fr) 2017-12-13
TW201639573A (zh) 2016-11-16
SV2017005489A (es) 2017-10-17
EA201791516A1 (ru) 2018-01-31
CL2017001943A1 (es) 2018-03-02
SG11201706107SA (en) 2017-08-30
CA2974828A1 (fr) 2016-08-11

Similar Documents

Publication Publication Date Title
MA41449A (fr) Polythérapies pour le traitement de cancers
MA49144A (fr) Polythérapies pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
HUE059694T2 (hu) Készítmény rák kezelésére
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
EP3362066A4 (fr) Polythérapie pour le traitement de tumeurs malignes
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3400011A4 (fr) Combinaisons anti-cd20 pour le traitement des tumeurs
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
EP3383547A4 (fr) Ensembles électromagnétiques pour le traitement de fluides
EP3359192A4 (fr) Polythérapie pour le traitement du cancer
MA41555A (fr) Polythérapie pour le traitement du cancer
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3383497A4 (fr) Nouveaux anticorps pour le traitement de cancers
EP3383407A4 (fr) Conjugués de cytarabine pour le traitement du cancer
EP4241647C0 (fr) Machine pour le traitement de surface
EP3331510A4 (fr) Thérapies combinatoires pour le traitement du cancer